UCCA LifeGel Fund

Medcura, Inc., a medical device company dedicated to transformatively improving the management of surgical bleeding, announced in January 2023 that the U.S. Food and Drug Administration (FDA) has granted the coveted Breakthrough Device Designation for its LifeGel™ Absorbable Surgical Hemostat. The FDA's Breakthrough Devices Program is available to therapeutic devices that establish they have the potential to provide more effective treatment of life threatening or irreversibly debilitating diseases or conditions. 

LifeGel™ is the first and only hemostatic agent to receive Breakthrough Device Designation seeking a new and highly differentiated indication: in surgical procedures (except in ophthalmic and urological) as an adjunctive hemostatic device when control of minimal, mild, and moderate bleeding by conventional procedures is ineffective or impractical. Due to its no-swell properties, LifeGel can be used in surgical procedures where swelling cannot be tolerated.

The Ukrainian Congress Committee of America, the nation's largest representation of Americans of Ukrainian descent, has created a special Humanitarian fund to provide as much LifeGel™ Absorbable Surgical Hemostat to Medical Facilities in Ukraine.

Beginning in February 2022, UCCA has regularly reported on the over $41 million in humanitarian aid and non-lethal assistance that has been delivered to Ukraine thanks to the generous, and fully tax-deductible donations to UCCA’s #SupportUkraineFund. UCCA values transparency which has once again earned UCCA a 2024 Platinum Seal of Transparency by Guidestar/Candid.